Key Points
- Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus at an average price of $8.79 for $105,480, leaving her with 44,997 shares — a 21.05% drop in her stake (SEC filing disclosed).
- Bioventus reported Q (Mar 5) earnings of $0.24 per share vs. $0.22 expected and revenue of $157.9M, set FY2026 EPS guidance of 0.730–0.770, and its shares trade around $8.62 with a 52-week range of $5.81–$10.13.
- Analysts have raised targets and ratings recently (average rating: "Buy", average price target $14.25), and institutional investors hold about 62.94% of the company’s stock.
Bioventus Inc. (NASDAQ:BVS - Get Free Report) Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total transaction of $105,480.00. Following the transaction, the director directly owned 44,997 shares of the company's stock, valued at approximately $395,523.63. This trade represents a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Bioventus Stock Up 0.2%
BVS stock opened at $8.62 on Friday. Bioventus Inc. has a one year low of $5.81 and a one year high of $10.13. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70. The firm's fifty day moving average is $8.25 and its 200 day moving average is $7.54. The firm has a market cap of $716.75 million, a PE ratio of 26.12 and a beta of 0.78.
Bioventus (NASDAQ:BVS - Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.02. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The business had revenue of $157.90 million during the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.
Analyst Ratings Changes
Several analysts have commented on the company. Barrington Research raised their price objective on Bioventus from $13.00 to $14.00 and gave the company an "outperform" rating in a report on Friday, March 6th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Bioventus in a research report on Monday, December 29th. Craig Hallum lifted their price target on shares of Bioventus from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Friday, March 6th. Finally, Cantor Fitzgerald raised shares of Bioventus to a "strong-buy" rating in a report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $14.25.
View Our Latest Analysis on Bioventus
Hedge Funds Weigh In On Bioventus
Hedge funds have recently made changes to their positions in the company. Marshall Wace LLP lifted its position in shares of Bioventus by 0.4% in the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company's stock valued at $2,149,000 after acquiring an additional 1,281 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company's stock worth $211,000 after purchasing an additional 1,538 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its stake in Bioventus by 16.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company's stock valued at $101,000 after purchasing an additional 1,887 shares during the last quarter. Deutsche Bank AG raised its stake in Bioventus by 8.2% in the 4th quarter. Deutsche Bank AG now owns 25,138 shares of the company's stock valued at $187,000 after purchasing an additional 1,908 shares during the last quarter. Finally, Covestor Ltd lifted its holdings in Bioventus by 28.0% in the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company's stock valued at $67,000 after purchasing an additional 2,176 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company's stock.
About Bioventus
(
Get Free Report)
Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
